A study to see how individualised homoeopathic treatment helps to reduce menstrual pain and improve quality of life in anaemic women

A prospective single-arm study on the effectiveness of individualised homoeopathic medicines in reducing pain and improving quality of life in primary dysmenorrhoea of anaemic females - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108119

Enrollment

Registered

2026-04-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

Intervention1: Individualised Homoeopathic Medicines: Individualised Homoeopathic Medicines in various potencies according to totality of symptoms and principles of homoeopathy for 4 months Control In

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients meeting the working case definition criteria 2.Females with haemoglobin level between 8.0-11.9 g/dl (mild and moderately anaemic females) 3.Females in the age group 18-35 years. 4.Cases with no pelvic pathology in USG abdomen and pelvis.

Exclusion criteria

Exclusion criteria: 1.Cases with pelvic pathology in USG abdomen and pelvis. 2.Cases with uncontrolled hypertension, diabetes mellitus, thyroid dysfunction and bleeding disorders. 3.Patients with heavy, prolonged and frequent menstrual bleeding. 4.Patients taking allopathic medications like NSAIDs and OCPs. 5.Patients with haemoglobin level less than 8.0g/dl and more than 11.9g/dl and those having unstable vital signs. 6.Patients with cognitive impairment.

Design outcomes

Primary

Measure	Time frame
Primary outcome measures will be based on assessment criteria. Assessment criteria- 1.WaLIDD (working ability, location, intensity, days of pain, dysmenorrhea)score 2.Quality Of Life Enjoyment and Satisfaction Questionnaire(Q-LES-Q-SF) scoreTimepoint: 1.WaLIDD score measured at the baseline and after 4 months of treatment. 2.Q-LES-Q-SF score measured at the baseline and after 4 months of treatment.	—

Measure

Time frame

Primary outcome measures will be based on assessment criteria. Assessment criteria- 1.WaLIDD (working ability, location, intensity, days of pain, dysmenorrhea)score 2.Quality Of Life Enjoyment and Satisfaction Questionnaire(Q-LES-Q-SF) scoreTimepoint: 1.WaLIDD score measured at the baseline and after 4 months of treatment. 2.Q-LES-Q-SF score measured at the baseline and after 4 months of treatment.

—

Secondary

Measure	Time frame
1. Change in Haemoglobin level 2. changes in WaLIDD score and Haemoglobin levelTimepoint: 1.Hb level measured at the baseline and after 4 months of treatment. 2.WaLIDD score and Hb level at the baseline and after 4 months of treatment.	—

Countries

India

Contacts

Public ContactDr Nimimole K L

Government Homoeopathic Medical College Kozhikode

nimimolekl@yahoo.com8075888791

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026